ECE2023 Poster Presentations Endocrine-related Cancer (62 abstracts)
Body composition of Patients with advanced Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs) in Spain: Nutrigetne Study
Maria Argente Pla 1 , Anna Casteras 2 , Miguel Giribes 2 , Beatriz Antón 3 , Maria Soledad Librizzi 4 , Ana Custodio Carretero 5 , Samara Palma Milla 6 , Lorena Suarez Gutierrez 7 , Inmaculada Peiró 8 , Leticia Serrano Urzaiz 9 , Soraya León-Idougourram 10 , Marta Dieguez Felechosa 11 , Beatriz Febrero 12 , Iulia Scorojanu 13 , Fernando Antonio Pazos Toral 14 , Josefina Biarnes 15 , Eider Pascual-Corrales 16 , Jose Angel Días-Pérez 17 , Miguel Antonio Sampedro-Nuñez 18 , Miguel Angel Martínez Olmos 19 , Andrea Micó García 1 & Maria Isabel Del Olmo Garcia 1
1University Hospital La Fe, Endocrinology and Nutrition, Valencia, Spain; 2Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Endocrinology and Nutrition, Barcelona, Spain; 3Hospital Universitario 12 de Octubre, Medical Oncology, Madrid, Spain; 4Hospital Universitario 12 de Octubre, Endocrinology and Nutrition, Madrid, Spain; 5Hospital Universitario La Paz, Medical Oncology, Madrid, Spain; 6Hospital Universitario La Paz, Endocrinology and Nutrition, Madrid, Spain; 7Hospital Universitario Central de Asturias, Endocrinology and Nutrition, Oviedo, Spain; 8Institut Català d’Oncologia (ICO), l’Hospitalet de Llobregat, Endocrinology and Nutrition, Barcelona, Spain; 9Hospital Universitario Miguel Servet, Endocrinology and Nutrition, Zaragoza, Spain; 10Hospital Universitario Reina Sofía, Endocrinology and Nutrition, Córdoba, Spain; 11Hospital Universitario de Cabueñes, Internal Medicine (Endocrinology and Nutrition), Gijón, Spain; 12Instituto Murciano de Investigación Biosanitaria (IMIB)- Arrixaca. Virgen de la Arrixaca University Hospital, Endocrine surgery, Murcia, Spain; 13Instituto Valenciano de Oncología (IVO), Nutrition department, Valencia, Spain; 14Hospital Universitario Marqués de Valdecilla, Endocrinology and Nutrition, Santander, Spain; 15Hospital Universitari de Girona Dr. Josep Trueta, Endocrinology and Nutrition, Girona, Spain; 16Hospital Ramón y Cajal, Endocrinology and Nutrition, Madrid, Spain; 17Hospital Universitario Clínico San Carlos, Endocrinology and Nutrition, Madrid, Spain; 18Hospital de La Princesa, Endocrinology and Nutrition, Madrid, Spain; 19Complejo Hospitalario Universitario de Santiago de Compostela. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Endocrinology and Nutrition, Santiago de Compostela, Spain
Introduction / Background: Patients with advanced GEP-NENs often present with metabolic disorders and oncological treatments may increase malnutrition risk as well as alterations on body composition. Several studies have suggested that sarcopenia is independently associated with a worse prognosis in oncological patients. Sarcopenia predicts survival regardless of body weight; moreover, a reduced muscle mass is not only observed in cachectic individuals but also in overweight patients.
Aims: The aim of this study is to describe body composition and to evaluate functionality of patients with advanced GEP NENs in Spain.
Materials and Methods: Cross-sectional study including patients with GEP-NENs at a metastatic/unresectable stage and active oncological treatment. Patients had a complete demographic evaluation, physical examination, anthropometry, bioelectrical impedance, dynamometry, laboratory analysis, and nutritional risk assessment. Malnutrition was defined according to GLIM criteria and sarcopenia according EWGSOP criteria. The study plans to include 400 patients; Accrual is open. Pearson’s χ2 test with α 0.05.
Results: 284 patients were included. Median age was 63 years (24-83). The most frequent tumor location was small bowel (44.7%) and pancreas (43%). 94.7% were metastatic, 88.4% grade 1-2 and 83.8% had ECOG 0-1, and 23.6% were functioning. The most common previous/current treatments were somatostatin analogues (89.8%), targeted therapy (29.9%), peptide receptor radionuclide therapy (28.9%) and chemotherapy (19.7%). 50% of the patients were on first line treatment, 23.9% on second line and 26% were on more than two lines. Malnutrition prevalence was 62% (n=176) being severe in37.7%(n=107). Low muscle mass was the most common GLIM phenotypic criteria, present in 139 patients (48.9%), being severe in 25.7%. Mean calf circumference was 34.2(4.8)cm and 36.5(5.5)cm, free fat mass of 41.4(10.6)kg and 56.1(11.8)kg and handgrip strength of 19.2(6.9)kg and 36.3(9.5)kg in females and males respectively. Mean phase angle was 7(9.3)° and 7(8.9)° in females and males respectively. Sarcopenia was present in 22.5%. Patients with malnutrition showed decreased handgrip strength (P<0.001).
Conclusions: Malnutrition among patients with advanced GEP-NENs is high, being low muscle mass the most frequent phenotypic criteria in patients with GEP-NENs present in half of the patients. One every five patients with GEP-NENs had sarcopenia.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more